A preliminary report of a phase II study of weekly topotecan in platinum-sensitive recurrent ovarian and peritoneal carcinoma

被引：0
|
作者：
Rodriguez, M
Method, MW
Lewandowski, G
Vaccarello, L
Ansari, RH
机构：
[1] Gynecol Oncol & Pelv Surg Associates, Columbus, OH USA
[2] Michiana Hematol Oncol, South Bend, IN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5063
引用
收藏
页码：464S / 464S
页数：1
相关论文
共 50 条
  • [21] A phase I study of lapatinib in combination with carboplatin in women with recurrent platinum-sensitive ovarian carcinoma
    Kimball, K. J.
    Numnum, T. M.
    Kirby, T. O.
    Zamboni, W. C.
    Estes, J. M.
    Barnes, M. N.
    Matei, D.
    Alvarez, R. D.
    GYNECOLOGIC ONCOLOGY, 2008, 108 (03) : S60 - S60
  • [22] A phase II trial of dolastatin-10 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study
    Hoffman, MA
    Blessing, JA
    Lentz, SS
    GYNECOLOGIC ONCOLOGY, 2003, 89 (01) : 95 - 98
  • [23] Phase II study of oxaliplatin (OXA) and docetaxel (DTX) in recurrent platinum-sensitive ovarian cancer
    Ferrandina, G
    Ludovisi, M
    Dagostino, G
    Lorusso, D
    Naldini, A
    Testa, AC
    Paris, I
    Gallotta, V
    Pozzo, C
    Scambia, G
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 468S - 468S
  • [24] A phase II study of gemcitabine, carboplatin and bevacizumab for the treatment of platinum-sensitive recurrent ovarian cancer
    Eisenhauer, Eric L.
    Zanagnolo, Vanna
    Cohn, David E.
    Salani, Ritu
    O'Malley, David M.
    Sutton, Gregory
    Callahan, Michael J.
    Cobb, Bobbi
    Fowler, Jeffrey M.
    Copeland, Larry J.
    GYNECOLOGIC ONCOLOGY, 2014, 134 (02) : 262 - 266
  • [25] A phase II trial of CI-958 in recurrent platinum-sensitive ovarian carcinoma:: A gynecologic oncology group study
    Hoffman, MA
    Blessing, JA
    Nuñez, ER
    GYNECOLOGIC ONCOLOGY, 2001, 81 (03) : 433 - 435
  • [26] Phase I pharmacology study of carboplatin and weekly paclitaxel in platinum-sensitive ovarian cancer patients with recurrent disease
    Aghajanian, C
    Sabbatini, P
    Hensley, M
    Spriggs, D
    SEMINARS IN ONCOLOGY, 1999, 26 (06) : 42 - 42
  • [27] A phase II study of gemcitabine, carboplatin and bevacizumab for the treatment of platinum-sensitive recurrent ovarian cancer
    Eisenhauer, E.
    Zanagnolo, V.
    Cohn, D.
    Salani, R.
    O'Malley, D.
    Sutton, G.
    Cobb, B.
    Vaughan, M.
    Fowler, J.
    Copeland, L.
    GYNECOLOGIC ONCOLOGY, 2011, 121 (01) : S31 - S31
  • [28] Gemcitabine plus carboplatin in platinum-sensitive recurrent ovarian carcinoma
    Kose, M. Faruk
    Meydanli, M. Mutlu
    Tulunay, Gokhan
    EXPERT REVIEW OF ANTICANCER THERAPY, 2006, 6 (03) : 437 - 443
  • [29] A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: A Gynecologic Oncology Group Study (GOG 146Q)
    Herzog, Thomas J.
    Sill, Michael W.
    Walker, Joan L.
    O'Malley, David
    Shahin, Mark
    DeGeest, Koen
    Weiner, Sheldon A.
    Mutch, David
    DeBernardo, Robert L.
    Lentz, Samuel S.
    GYNECOLOGIC ONCOLOGY, 2011, 120 (03) : 454 - 458
  • [30] PHASE II TRIAL OF LAPATINIB IN COMBINATION WITH WEEKLY TOPOTECAN IN PATIENTS WITH PLATINUM-REFRACTORY/RESISTANT OVARIAN AND PRIMARY PERITONEAL CARCINOMA
    Haluska, P.
    Oberg, A. L.
    Dakhil, S. R.
    Ziegler, K. L. Allen
    Rowland, K. M.
    Hartmann, L. C.
    Moore, D. F.
    Keeney, G. L.
    Peethambaram, P. P.
    ANNALS OF ONCOLOGY, 2009, 20 : 43 - 43
12345